Preclinical development of PKMYT1 and WEE1 inhibitor combinations

被引：0
|
作者：
Gallo, David
Shah, Fenil
Stocco, Rino
Baruah, Prasamit
Fourtounis, Jimmy
Kryczka, Rosie
Hyer, Marc L.
Roulston, Anne
Marshall, C. Gary
Zimmermann, Michal
Morris, Stephen
Zinda, Michael
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-A023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Abstract A
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Preclinical development of PKMYT1 and ATR inhibitor combinations
    Gallo, David
    Hyer, Marc L.
    Martino, Giovanni
    Pertrone, Adam
    Aguado-Fraile, Elia
    Kryczka, Rosie
    Fourtounis, Jimmy
    Stocco, Rino
    Morris, Stephen J.
    Marshall, C. Gary
    Roulston, Anne
    Zinda, Michael
    Zimmermann, Michal
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [2] PKMYT1: a forgotten member of the WEE1 family
    Asquith, Christopher R. M.
    Laitinen, Tuomo
    East, Michael P.
    NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (03) : 157 - 157
  • [3] Structural and energetic insights into the selective inhibition of PKMYT1 against WEE1
    Qi, Xuesen
    Li, Guozhen
    Liu, Jiahai
    Mou, Linkai
    Zhang, Yusheng
    Guo, Shilin
    Chen, Xiangyu
    Li, Wenxing
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024, 42 (06): : 3010 - 3018
  • [4] Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases
    Schmidt, Matthias
    Rohe, Alexander
    Platzer, Charlott
    Najjar, Abdulkarim
    Erdmann, Frank
    Sippl, Wolfgang
    MOLECULES, 2017, 22 (12):
  • [5] Dual Inhibition of WEE1 and PKMYT1 Synergistically Overcomes CDK4/6 Inhibitor Resistance in Breast Cancer
    Chen, Mei-Kuang
    DeAlessandro, Grace
    Bui, Tuyen
    Keyomarsi, Khandan
    CANCER RESEARCH, 2024, 84 (09)
  • [6] Pediatric DDR inhibitor combinations: Are WEE1 there yet?
    Slotkin, Emily K.
    Ortiz, Michael V.
    Bender, Julia L. Glade L.
    CANCER, 2023, 129 (14) : 2132 - 2134
  • [7] WEE1 Inhibitor: Clinical Development
    Anthony Kong
    Hisham Mehanna
    Current Oncology Reports, 2021, 23
  • [8] WEE1 Inhibitor: Clinical Development
    Kong, Anthony
    Mehanna, Hisham
    CURRENT ONCOLOGY REPORTS, 2021, 23 (09)
  • [9] PD0166285 sensitizes esophageal squamous cell carcinoma to radiotherapy by dual inhibition of WEE1 and PKMYT1
    Zhang, Qingyi
    Lin, Xu
    Jiang, Kan
    Deng, Jun
    Ke, Lei
    Wu, Ziheng
    Xia, Pinghui
    Li, Qi
    Yu, Li
    Ni, Pengzhi
    Lv, Wang
    Hu, Jian
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Rational design of a superior single agent active, potential best-in-class WEE1/PKMYT1 inhibitor using Acrivon Predictive Precision Proteomics (AP3)
    Baddour-Sousounis, J.
    Pasetto, M.
    Nilsson, H.
    Mitsa, G.
    Shi, L.
    Lombardo, P.
    Best, Z.
    Improgo, R.
    Kumar, S.
    Rappard, K.
    Hay, E.
    Muralitharan, U.
    Murshid, A.
    Shipitsin, M.
    Wigerup, C.
    Jakobsson, M. E.
    Jung, J.
    Proia, D. A.
    Masson, K.
    Blume-Jensen, P.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S124 - S124
12345